Cargando…
Targeted Drug Delivery for the Treatment of Blood Cancers
Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers. Chemotherapy is the major therapy of blood cancers by systemic administration of anticancer agents into the blood. However,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880555/ https://www.ncbi.nlm.nih.gov/pubmed/35209102 http://dx.doi.org/10.3390/molecules27041310 |
_version_ | 1784659241678667776 |
---|---|
author | Jiang, Yao Lin, Weifeng Zhu, Linyi |
author_facet | Jiang, Yao Lin, Weifeng Zhu, Linyi |
author_sort | Jiang, Yao |
collection | PubMed |
description | Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers. Chemotherapy is the major therapy of blood cancers by systemic administration of anticancer agents into the blood. However, a high incidence of relapse often happens, due to the low efficiency of the anticancer agents that accumulate in the tumor site, and therefore lead to a low survival rate of patients. This indicates an urgent need for a targeted drug delivery system to improve the safety and efficacy of therapeutics for blood cancers. In this review, we describe the current targeting strategies for blood cancers and recently investigated and approved drug delivery system formulations for blood cancers. In addition, we also discuss current challenges in the application of drug delivery systems for treating blood cancers. |
format | Online Article Text |
id | pubmed-8880555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88805552022-02-26 Targeted Drug Delivery for the Treatment of Blood Cancers Jiang, Yao Lin, Weifeng Zhu, Linyi Molecules Review Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers. Chemotherapy is the major therapy of blood cancers by systemic administration of anticancer agents into the blood. However, a high incidence of relapse often happens, due to the low efficiency of the anticancer agents that accumulate in the tumor site, and therefore lead to a low survival rate of patients. This indicates an urgent need for a targeted drug delivery system to improve the safety and efficacy of therapeutics for blood cancers. In this review, we describe the current targeting strategies for blood cancers and recently investigated and approved drug delivery system formulations for blood cancers. In addition, we also discuss current challenges in the application of drug delivery systems for treating blood cancers. MDPI 2022-02-15 /pmc/articles/PMC8880555/ /pubmed/35209102 http://dx.doi.org/10.3390/molecules27041310 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jiang, Yao Lin, Weifeng Zhu, Linyi Targeted Drug Delivery for the Treatment of Blood Cancers |
title | Targeted Drug Delivery for the Treatment of Blood Cancers |
title_full | Targeted Drug Delivery for the Treatment of Blood Cancers |
title_fullStr | Targeted Drug Delivery for the Treatment of Blood Cancers |
title_full_unstemmed | Targeted Drug Delivery for the Treatment of Blood Cancers |
title_short | Targeted Drug Delivery for the Treatment of Blood Cancers |
title_sort | targeted drug delivery for the treatment of blood cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880555/ https://www.ncbi.nlm.nih.gov/pubmed/35209102 http://dx.doi.org/10.3390/molecules27041310 |
work_keys_str_mv | AT jiangyao targeteddrugdeliveryforthetreatmentofbloodcancers AT linweifeng targeteddrugdeliveryforthetreatmentofbloodcancers AT zhulinyi targeteddrugdeliveryforthetreatmentofbloodcancers |